| Market Cap | 70.95B | P/E | 10.69 | EPS this Y | 10.90% | Ern Qtrly Grth | -27.80% |
| Income | 4.03B | Forward P/E | 8.79 | EPS next Y | 10.30% | 50D Avg Chg | -1.00% |
| Sales | 31.45B | PEG | 7,198.60 | EPS past 5Y | 1.60% | 200D Avg Chg | - |
| Dividend | 3.00% | Price/Book | 5.53 | EPS next 5Y | 0.10% | 52W High Chg | -16.00% |
| Recommedations | 3.00 | Quick Ratio | 0.53 | Shares Outstanding | 4.08B | 52W Low Chg | 29.00% |
| Insider Own | 1.61% | ROA | 9.56% | Shares Float | 3.95B | Beta | 0.31 |
| Inst Own | 45.76% | ROE | 33.30% | Shares Shorted/Prior | -/- | Price | 17.33 |
| Gross Margin | 72.78% | Profit Margin | 12.83% | Avg. Volume | 2,458 | Target Price | - |
| Oper. Margin | 28.10% | Earnings Date | Oct 30 | Volume | 363 | Change | -5.17% |
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
